Use of eif5b in treating leukemia

By using EIF5B inhibitors, especially shRNA, to inhibit the expression or activity of EIF5B, the problems of drug resistance and relapse in acute myeloid leukemia have been solved, achieving selective inhibition and therapeutic effects on AML cells and improving patient survival rates.

CN120714043BActive Publication Date: 2026-06-23INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
Filing Date
2025-07-10
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Current technologies are insufficient to effectively treat acute myeloid leukemia, especially due to drug resistance and relapse caused by high expression of EIF5B, which affects patient survival rates.

Method used

Methods for developing drugs to treat leukemia and screening candidate drugs include using EIF5B inhibitors, including nucleic acid inhibitors such as shRNA, to inhibit the expression or activity of EIF5B.

Benefits of technology

EIF5B inhibitors selectively inhibit the proliferation and cell cycle of AML cells, reducing colony formation without affecting the function of normal hematopoietic stem cells, providing a broad-spectrum therapeutic target for AML and improving patient survival rates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120714043B_ABST
    Figure CN120714043B_ABST
Patent Text Reader

Abstract

The application discloses an application of EIF5B in treating leukemia. The application firstly discovers that a translation initiation factor EIF5B is universally highly expressed in patients of various subtypes of AML, the EIF5B is specifically involved in maintaining the function of AML cell lines, does not affect the function of normal HSPC, and is expected to become a broad-spectrum AML treatment target.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • CN103656674A

  • US20150147271A1